In a quarterly disclosure with the SEC, Farallon Capital Management revealed it established a new position in Tango Therapeutics (TNGX) by purchasing 9.10 million shares. The newly acquired stake was valued at $190.32 million and accounted for a 1.08% weight in the major investment firm's portfolio.
This 13F filing, made public on August 14, 2026, reflects the firm's holdings as of March 31, 2026, and does not represent a real-time trade. During the first quarter, Tango Therapeutics reported its financial results, noting it held $379.8 million in cash and cash equivalents, which it expects to fund operations into 2028. The company is focused on advancing its pipeline of precision cancer medicines.